# AstraZeneca and Daiichi Sankyo’s Dato-DXd validated by EMA for lung and breast cancer treatment

- Link: https://www.directorstalkinterviews.com/astrazeneca-and-daiichi-sankyos-dato-dxd-validated-by-ema-for-lung-and-breast-cancer-treatment/4121145772
- Published: 2024-03-04T07:22:06+00:00
- Author: Amilia Stone

**[AstraZeneca plc](https://www.directorstalkinterviews.com/ftse-company/astrazeneca/azn.l)**(
[LON:AZN](https://www.directorstalkinterviews.com/ftse-company/astrazeneca/azn.l))
has announced that the European Medicines Agency (EMA) has validated two marketing
authorisation applications (MAAs) for AstraZeneca and Daiichi Sankyo’s datopotamab
deruxtecan (Dato-DXd) in two types of cancer. One MAA is for the treatment of adult
patients with locally advanced or metastatic nonsquamous non-small cell lung cancer(
NSCLC) who require systemic therapy following prior treatment. The other MAA is 
for the treatment of adult patients with unresectable or metastatic hormone receptor(
HR)-positive, HER2-negative (IHC 0, IHC 1+ or IHC 2+/ISH-) breast cancer who have
progressed on and are not suitable for endocrine therapy and received at least one
additional systemic therapy.

The validations confirm the completion of the applications and commence the scientific
review process by the EMA’s Committee for Medicinal Products for Human Use. The 
applications are based on data from the pivotal TROPION-Lung01 and TROPION-Breast01
Phase III trials presented during two Presidential Symposia at the 2023 European
Society for Medical Oncology Congress.

Datopotamab deruxtecan is a specifically engineered TROP2-directed DXd antibody 
drug conjugate (ADC) discovered by Daiichi Sankyo and being jointly developed by
AstraZeneca and Daiichi Sankyo.

> **Susan Galbraith, Executive Vice President, Oncology R&D, AstraZeneca, said**:“
> Our ambition is for datopotamab deruxtecan to improve upon and replace conventional
> chemotherapy in the treatment of multiple cancer types. Today’s dual validation
> of our applications in lung and breast cancers brings this potential medicine 
> a meaningful step closer to redefining treatment expectations for patients with
> two of the most common cancers in Europe.”

> **Ken Takeshita, MD, Global Head, R&D, Daiichi Sankyo, said**: “The EMA validation
> is an important first step toward bringing this TROP2-directed antibody drug conjugate
> to eligible patients in Europe with nonsquamous lung cancer and HR-positive, HER2-
> negative breast cancer. This news builds on our recent regulatory progress in 
> the US, where our lung cancer application has been accepted and our breast cancer
> application is underway, underscoring our commitment to changing the standard 
> of care by developing new medicines to help as many patients worldwide as possible.”

Additional regulatory submissions for datopotamab deruxtecan in lung cancer and 
breast cancer are underway in the US and globally.

**Datopotamab deruxtecan (Dato-DXd)**

Datopotamab deruxtecan (Dato-DXd) is an investigational TROP2-directed ADC. Designed
using Daiichi Sankyo’s proprietary DXd ADC Technology, datopotamab deruxtecan is
one of six DXd ADCs in the oncology pipeline of Daiichi Sankyo, and one of the most
advanced programmes in AstraZeneca’s ADC scientific platform. Datopotamab deruxtecan
is comprised of a humanized anti-TROP2 IgG1 monoclonal antibody, developed in collaboration
with Sapporo Medical University, attached to a number of topoisomerase I inhibitor
payloads (an exatecan derivative, DXd) via tetrapeptide-based cleavable linkers.

Share on:
